Trial reportPsychopharmacology2007
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Trial report in Psychopharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 63 citations in OpenAlex.
- PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.Psychopharmacology · 2006Trial
- Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.Current topics in medicinal chemistry · 2024Review
- Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.Current Alzheimer research · 2021Review
- CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.Frontiers in molecular neuroscience · 2019Article
- Development and optimization of a novel automated loop method for production of [Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2018Article
- Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.Frontiers in pharmacology · 2016Review
- PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis.Current cardiology reports · 2015Review
- Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.Psychopharmacology · 2013Article
- The human frontal lobes and frontal network systems: an evolutionary, clinical, and treatment perspective.ISRN neurology · 2013Article
- A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.The primary care companion for CNS disorders · 2013Article
- Advances in functional neuroimaging in dementias and potential pitfalls.Neurology international · 2012Article
- Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Alzheimer's research & therapy · 2011Article
- Article
- Neuroimaging in dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2011Review
- The use of PET in Alzheimer disease.Nature reviews. Neurology · 2010Review
- A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of Schizophrenia.Journal of dual diagnosis · 2009Article
- Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.Psychopharmacology · 2009Article
- Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.Journal of neural transmission (Vienna, Austria : 1996) · 2008Article
- The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.Molecular neurobiology · 2008Review
- Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.Neuropsychiatric disease and treatment · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleMarked reduction in the cortical nicotinic acetylcholine receptors is observed in the brain of patients suffering from Alzheimer's disease (AD). Although cholinesterase inhibitors are used for symptomatic treatment of mild to moderate AD patients, numerous long-term treatment studies indicate that they might stabilize or halt the progression of the disease by restoring the central cholinergic neurotransmission. Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD.
objectiveTo evaluate changes in brain nicotinic binding sites in relation to inhibition level of cholinesterases in cerebrospinal fluid (CSF) and plasma and changes in cognitive performance of the patients in different neuropsychological tests after rivastigmine treatment. MATERIALS AND
methodsTen mild AD patients received rivastigmine for 12 months. A dual-tracer PET model with administration of (15)O-water and (S)(-)(11)C-nicotine was used to assess (11)C-nicotine binding sites in the brain at baseline and after 3 and 12 months of the treatment. Cholinesterase activities in CSF and plasma were assessed colorimetrically.
resultsThe (11)C-nicotine binding sites were significantly increased 12-19% in several cortical brain regions after 3 months compared with baseline, while the increase was not significant after 12 months of the treatment. After 3 months treatment, low enzyme inhibition in CSF and plasma was correlated with higher cortical (11)C-nicotine binding. The (11)C-nicotine binding positively correlated with attentional task at the 12-month follow-up.
conclusionChanges in the (11)C-nicotine binding during rivastigmine treatment might represent remodeling of the cholinergic and related neuronal network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.